ISIS 702843

Drug Profile

ISIS 702843

Alternative Names: IONIS TMPRSS6-Lrx; ISIS-702843

Latest Information Update: 08 Jun 2017

Price : $50

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action TMPRSS6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thalassaemia

Most Recent Events

  • 06 Jun 2017 Phase-I clinical trials in Thalassaemia (In volunteers) in Australia (SC) (NCT03165864)
  • 31 Mar 2017 Ionis Pharmaceuticals and INC Research Australia plan a phase I trial in Healthy volunteers in Australia and USA (SC, Injection) (1056098; ACTRN12617000458336p)
  • 30 Mar 2017 Preclinical trials in Thalassaemia in Australia, USA (SC), before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top